Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Clinical trial NCT05180097 · RECRUITING
Trial details
- NCT number
- NCT05180097
- Sponsor
- Canadian Cancer Trials Group
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-01
- Primary completion
- 2026-12-31
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.